Haleon plc (HLN)vsEli Lilly and Company (LLY)
HLN
Haleon plc
$9.36
+0.86%
HEALTHCARE · Cap: $40.48B
LLY
Eli Lilly and Company
$1,170.45
+0.45%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 614% more annual revenue ($79.67B vs $11.15B). LLY leads profitability with a 33.5% profit margin vs 14.5%. LLY appears more attractively valued with a PEG of 1.11. LLY earns a higher WallStSmart Score of 76/100 (B+).
HLN
Buy51
out of 100
Grade: C-
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
HLN profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 51/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?